Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individuals Who Have Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00588263|
Recruitment Status : Withdrawn (Data from MSK-IMPACT is sufficient for relevant analyses going forward)
First Posted : January 8, 2008
Last Update Posted : February 16, 2018
|Condition or disease|
|Extrahepatic Bile Duct Cancer Gallbladder Cancer Gastric Cancer Lung Cancer Melanoma Non-Hodgkin's Lymphoma Uterine Cancer CORPUS UTERI,ENDOMETRIUM LUNG OVARY|
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Official Title:||Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individual With Cancer|
|Study Start Date :||July 2000|
|Estimated Primary Completion Date :||July 2018|
|Estimated Study Completion Date :||July 2018|
- determine the prevalence of recurring BRCA1 and BRCA2 mutations [ Time Frame: 5 years ]
Biospecimen Retention: Samples With DNA
Blocks or extracted DNA from patients who have identified themselves as Jewish will be obtained and a determination will be made as to whether there is adequate material to proceed without exhausting the block or extracted DNA.
Four unstained sections (research specimens) or paraffin "curls" will be cut from each block. In those cases where a block containing normal resection margin or any other biopsy of normal tissue are available, tissue will be cut from this block so as to preserve tumor tissue for later investigators. It is not necessary for sections to be reviewed to confirm that tumor is present in the section, since any germline DNA is adequate for this analysis.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00588263
|United States, New York|
|Memorial Sloan Kettering Cancer Center|
|New York, New York, United States, 10065|
|Principal Investigator:||Kenneth Offit, M.D.||Memorial Sloan Kettering Cancer Center|